lukrvoek

JPL’s Mars Curiosity Rover Suffers Malfunction

first_img Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Science and Technology JPL’s Mars Curiosity Rover Suffers Malfunction From JPL/CALTECH/NASA Published on Wednesday, December 14, 2016 | 8:24 pm Business News Subscribe Community News Herbeauty7 Most Startling Movie Moments We Didn’t Realize Were InsensitiveHerbeautyHerbeautyHerbeauty10 Of The Most Notorious Female Spies In HistoryHerbeautyHerbeautyHerbeautyThese Are 15 Great Style Tips From Asian WomenHerbeautyHerbeautyHerbeautyWeird Types Of Massage Not Everyone Dares To TryHerbeautyHerbeautyHerbeauty9 Of The Best Family Friendly Dog BreedsHerbeautyHerbeautyHerbeauty8 Celebrities People Don’t Love AnymoreHerbeautyHerbeauty Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. 14 recommended0 commentsShareShareTweetSharePin it More Cool Stuff The Curiosity rover’s robotic arm is not functioning properly, endangering its scientific mission. NASA/JPL-CaltechEngineers at NASA’s Jet Propulsion Laboratory in Pasadena are trying to fix a problem with the Mars Curiosity rover’s drill mechanism, as the vehicle remains stationary on the red planet.The rover team at JPL learned on December 1 that Curiosity did not complete the commands for drilling. The rover detected a fault in the “drill feed” mechanism that prevented the drill from touching the rock target.“We are in the process of defining a set of diagnostic tests to carefully assess the drill feed mechanism. We are using our test rover here on Earth to try out these tests before we run them on Mars,” Curiosity Deputy Project Manager Steven Lee at JPL said Monday. “To be cautious, until we run the tests on Curiosity, we want to restrict any dynamic changes that could affect the diagnosis. That means not moving the arm and not driving, which could shake it.”“We said ‘go,’ and it just didn’t go,” says Ashwin Vasavada, a project scientist at JPL told NPR.The drill feed mechanism pushes the front of the drill outward from the turret of tools at the end of Curiosity’s robotic arm. The drill collects powdered rock that is analyzed by laboratory instruments inside the rover.Even as it remains stranded, the rover is studying its surroundings and monitoring the environment, rather than driving or using its arm for science.‘We’re keeping busy with using the other instruments on the rover while they do these tests,’ said Ashwin Vasavada, project scientist.At its current location, Curiosity has driven 9.33 miles since landing inside Mars’ Gale Crater in August 2012. That includes more than half a mile since departing a cluster of scenic mesas and buttes – called “Murray Buttes” – in September. Curiosity has climbed 541 feet in elevation since landing, including 144 feet since departing Murray Buttes, according to NASA.Since 2012, Curiosity has uncovered geologic evidence of an ancient environment that could have supported primitive life early in the red planet’s history. At Mount Sharp, the rover plans to climb to higher and younger rock formations.Before the drill mechanism snag, the six-wheel rover found more evidence of a watery history on the slopes of Mount Sharp including the presence of certain chemicals that suggests a warmer and wetter past unlike the current frigid, harsh environment.JPL, a division of Caltech, manages NASA’s Mars Science Laboratory Project for NASA’s Science Mission Directorate in Washington, and built the Curiosity rover.For more information about the mission, visit www.mars.jpl.nasa.gov/msl. First Heatwave Expected Next Week center_img Your email address will not be published. Required fields are marked * Community News faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyCitizen Service CenterPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Top of the News Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Name (required)  Mail (required) (not be published)  Website  EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Make a comment Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadenalast_img read more

lukrvoek

VarmX appoints Dr. Gerard Short as Chief Medical Officer

first_imgLocal NewsBusiness VarmX appoints Dr. Gerard Short as Chief Medical Officer WhatsApp LEIDEN, The Netherlands–(BUSINESS WIRE)–Jan 27, 2021– VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr. Short will be responsible for overseeing the clinical development of VarmX’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies. Dr. Short brings to VarmX extensive clinical development expertise, with a particular focus on rare diseases and gene therapy for haematological disorders. With more than 20 years of experience working within the sector – for both big pharma and biotech – he has established a strong track record of successfully leading teams in clinical development and medical affairs. Alexander Vos, CEO of VarmX, said:“We are delighted to welcome a person of Gerard’s calibre to our team. His proven knowledge in clinical, medical, and regulatory affairs, combined with his history of successfully advancing programs into the clinic, will be instrumental as VarmX enters a key transition phase to becoming a clinical stage company in 2021.” “I’m pleased to be joining VarmX at this stage in the Company’s evolution,”commented Dr. Gerard Short, CMO of VarmX, on his appointment.“I recognise the potential that the lead compound, VMX-C001, holds as an effective and differentiated antidote to oral anticoagulants, reversing the severe consequences that patients face. As such, I look forward eagerly to further progress the program towards the start of clinical studies later this year.” Dr. Short joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science. During this time, he grew the medical, clinical, and regulatory groups, and established an in-house pharmacovigilance function. Further, he advanced gene therapy clinical programmes in haemophilia B and Fabry’s disease. Before Freeline, Dr. Short spent a decade at Genzyme, preceding and following its acquisition by Sanofi. He held roles of increasing responsibility, ultimately serving as Global Development Team Leader leading innovative treatment programmes targeting Pompe’s disease (phase 3) and acute leukaemia. Prior to Genzyme, Dr. Short established his clinical development career through a series of roles at Novartis, Pfizer and Sanofi-Synthelabo following eight years as a clinical practitioner. Dr. Short received his Bachelor of Medicine (MBBS) degree from St. Mary’s Hospital Medical School (now part of Imperial College) and holds a Master of Business Administration (MBA) degree from London Business School. In addition, he is a Member of the Royal College of Physicians (MRCP UK) and a Fellow of the Faculty of Pharmaceutical Medicine (FFPM). ENDS Notes to Editors About VarmX VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X based on the venom of the Australian brown snake, Pseudonaja textilis. The compound is being developed for the treatment of severe spontaneous bleeding in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Ysios Capital, INKEF Capital, Lundbeckfonden Ventures, LSP, BioGeneration Ventures and the regional economic development fund, InnovationQuarter. For more information: www.varmx.com. View source version on businesswire.com:https://www.businesswire.com/news/home/20210126006023/en/ CONTACT: VarmX B.V. Alexander Vos, CEO Tel: +31 6 46 736 915Instinctif Partners (media enquiries) Melanie Toyne-Sewell / Nathan Billis Tel: +44 20 7457 2020Leon Melens (Dutch press) Tel: +31 6 538 16 427 E-mail:[email protected] KEYWORD: EUROPE UNITED STATES NETHERLANDS NORTH AMERICA NEW YORK INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: VarmX Copyright Business Wire 2021. PUB: 01/27/2021 02:00 AM/DISC: 01/27/2021 02:00 AM http://www.businesswire.com/news/home/20210126006023/en Pinterest Twitter By Digital AIM Web Support – January 27, 2021 Facebookcenter_img Twitter Facebook TAGS  WhatsApp Pinterest Previous articleLes solutions CECL de Moody’s Analytics passent avec succès les évaluations SOC 1® 2020Next articleMediaKind Wins Two Technology & Engineering Emmy® Awards for Pioneering Development of Event Signaling and Management API, and AI/Optimization for Real-Time Video Compression Digital AIM Web Supportlast_img read more